MultiTAA T cell therapy

News alerts, weekly reports and conference planners

Company:

Baylor College of Medicine, Marker Therap

Drug class:

MAGE-A4 inhibitor, NY ESO 1 inhibitor, Survivin inhibitor, PRAME inhibitor, SSX2 inhibitor, Tumor-associated antigen inhibitor

Related drugs:

‹

›

11ms

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)

P1, N=44, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024

11 months ago

Trial primary completion date

KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)

MultiTAA T cell therapy

almost2years

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. (PubMed, Ther Adv Med Oncol)

This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC.

almost 2 years ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma)

ER positive + PGR positive • PGR positive • EGFR positive • BIRC5 expression

MultiTAA T cell therapy

almost2years

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)

P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Apr 2022 --> Apr 2023

almost 2 years ago

Trial completion date • Trial primary completion date

KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule)

MultiTAA T cell therapy